<?xml version="1.0" encoding="UTF-8"?>
<p>Rhamnolipids have been reported to have antiviral activity against the herpes simplex virus (HSV) types I and II [
 <xref rid="B135-pharmaceutics-12-00688" ref-type="bibr">135</xref>]. The effect was dose dependent and occurred at concentrations below the critical micelle concentration of the rhamnolipid. One of the first reports on the antiviral activity of SLs was presented by Shah et al. [
 <xref rid="B136-pharmaceutics-12-00688" ref-type="bibr">136</xref>]. The authors discovered an anti-human immunodeficiency virus (HIV) activity of the tested SLs together with a spermicidal activity comparable with nonoxynol-9. The potential activity of SLs against retrovirus, herpes virus and papillomavirus has been the subject of several patents [
 <xref rid="B137-pharmaceutics-12-00688" ref-type="bibr">137</xref>,
 <xref rid="B138-pharmaceutics-12-00688" ref-type="bibr">138</xref>]. Moreover, the report by Gross et al. [
 <xref rid="B137-pharmaceutics-12-00688" ref-type="bibr">137</xref>] also presented the influence of SLs on the Epsteinâ€“Barr virus. 
</p>
